Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.840
-0.150 (-7.54%)
Jan 15, 2026, 4:00 PM EST - Market closed
Pyxis Oncology Employees
Pyxis Oncology had 44 employees as of December 31, 2024. The number of employees decreased by 6 or -12.00% compared to the previous year.
Employees
44
Change (1Y)
-6
Growth (1Y)
-12.00%
Revenue / Employee
$64,091
Profits / Employee
-$2,206,500
Market Cap
114.57M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44 | -6 | -12.00% |
| Dec 31, 2023 | 50 | -25 | -33.33% |
| Dec 31, 2022 | 75 | 19 | 33.93% |
| Dec 31, 2021 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PYXS News
- 27 days ago - Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
- 4 weeks ago - Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript - Seeking Alpha
- 4 weeks ago - Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - GlobeNewsWire
- 2 months ago - Pyxis Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings - GlobeNewsWire
- 3 months ago - Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - GlobeNewsWire
- 3 months ago - Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire